WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR 1 January 2021 Issue has been Published, Kindly check it on http://www.wjahr.com/home/current_issues

  • WJAHR JANUARY ISSUE PUBLISHED

    JANUARY 2021 Issue has been successfully launched on 1 January 2021.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

EFFECT OF SACUBITRIL/VALSARTAN ON HEART RATE VARIABILITY HRV AND QT DISPERSION IN HEART FAILURE WITH REDUCED EJECTION FRACTION

Waleed Shehab Aladib* and Houssam Balleh

ABSTRACT

Background: Treatment of heart failure with reduced ejection fraction(HFrEF) by using Sacubitril/Valsartan reduces sudden cardiac death, but the precise mechanism underlying the beneficial effect on reducing cardiovascular mortality is still not clear. Objective: the present study aims to assess effects of Sacubitril/Valsartan on QT dispersion and HR variability in symptomatic patients with HFrEF. Materials and Methods: This is prospective study conducted in the department of Cardiology in Tishreen University Hospital-Lattakia -Syria from September 2019 to September 2020. Patients with HFrEF classified according to the NYHA in II-IV who aged 39 to 82 years were enrolled in the study. QT dispersion, SDNN were reordered before starting Sacubitril/Valsartan and after one month of the therapy. Results: A total of 22 patients were included, Median age was 50 years, 13 (59.10%) were female, hypertension was present in 15(68.2%) of the patients. Sacubitril/Valsartan reduced QTd (65.09±25.3 vs 51.72±21.7, p:0.004), OTc(435.04±27.6 vs 425.40±27.1.p:0.1), QRS(94.54±19.22 vs 93.40±16.39,p:0.6), and increased SDNN(93.22±24.7 vs 111.81±37.2,p:0.01) in the study participants. Spearman's correlation analysis revealed negative correlation between changes in SDNN and dyspnea degree (Spearman's = -0.2, P:0.04) and a positive correlation between changes in QTD and dyspnea degree (Spearman's = 0.3, P:0.01). Increased dose of drug was correlated with decreased QTd(Spearman's = - 0.1, P:0.5) and increased SDNN(Spearman's = 0.1, P:0.4). Conclusion: Based on our results, Sacubitril/Valsartan alters ventricular repolarization indices which associated with clinical improvement, so it could be an effective approach in treating patients with HFrEF.

[Full Text Article]